“Gone are the days when scalpel was king or queen in this space. The armamentarium of medications and systemic treatments, combination treatments has exploded, and our understanding of the biology of disease is expanding,” says Harras B. Zaid, MD.
In this video, Harras B. Zaid, MD, discusses treatment advances in the management of renal cell carcinoma (RCC), which was discusses during a session at SUO titled, “Panel Discussion: Salvage Therapies for Recurrence Following Local Therapy (Ablation, Systemic Therapy, XRT, Surgery).” Zaid is an assistant professor in the department of surgery and perioperative care at the University of Texas, Austin and a urologic oncologist at Dell Seton Medical Center.
Video Transcript:
One of the things that the panel discussion kept coming home to is that this is multidisciplinary approach. Gone are the days when scalpel was king or queen in this space. The armamentarium of medications–systemic treatments, combination treatments–has exploded, and our understanding of the biology of disease is expanding. Also non-surgical techniques–SBRT, thermal ablation techniques–have become more sophisticated. Before as surgeons we go in and operate in this disease space, we really need to think long and hard, engage our colleagues in medical and radiation oncology, and most importantly, have an honest discussion with our patients and their families, weighing the risks and benefits of upfront surgery versus upfront treatment. Patients and families will have priorities; financial toxicities and treatment fatigue need to be considered. I think all of these are now part of our care package of these patients.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.